Aromatase inhibitors and mammographic breast density in postmenopausal women receiving hormone therapy

Menopause

Volumn 15, Issue 5, 2008, Pages 875-884

  Mousa, Noha A ^a,b   Crystal, Pavel ^b   Wolfman, Wendy L ^b   Bedaiwy, Mohamed A ^c   Casper, Robert F ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Aromatase inhibitors; Breast cancer; Breast density; Chemoprevention; Computer assisted image analysis; Hormone therapy; Mammogram

Indexed keywords

ANASTROZOLE; ESTRADIOL; LETROZOLE; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; PROGESTERONE; AROMATASE INHIBITOR; ESTROGEN;

ADULT; ARTICLE; BONE DENSITY; BREAST CANCER; BREAST DENSITY; CANCER RISK; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER PROGRAM; CONTROLLED STUDY; DENSITY; DEPRESSION; DIARRHEA; DRUG EFFECT; DRUG WITHDRAWAL; DYSPAREUNIA; EARLY MENOPAUSE; FEMALE; HEADACHE; HORMONAL THERAPY; HOT FLUSH; HUMAN; IMAGE ANALYSIS; LIBIDO DISORDER; LOW DRUG DOSE; MAMMOGRAPHY; MOOD DISORDER; MUSCULOSKELETAL PAIN; NAUSEA; NIGHT SWEAT; OSTEOPOROSIS; OUTCOME ASSESSMENT; POSTMENOPAUSE; RETROSPECTIVE STUDY; UNIVERSITY HOSPITAL; VAGINAL DRYNESS; VOMITING; BREAST DISEASE; BREAST TUMOR; CASE CONTROL STUDY; DRUG COMBINATION; ESTROGEN THERAPY; MIDDLE AGED; TREATMENT OUTCOME; WOMEN'S HEALTH;

AROMATASE INHIBITORS; BONE DENSITY; BREAST DISEASES; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; POSTMENOPAUSE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; WOMEN'S HEALTH;

EID: 58249085105     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31816956c3     Document Type: Article

References (78)

1. WHO 2006 Fact Sheet. Available at: http://www.whoint/mediacentre/ factsheets/fs297/en/indexhtml. Accessed August, 2007.
2. NCI 2007. Available at: http://www.ncic.cancer.ca/ncic/internet/standard/ 0,3621,84658243-85787780-1834604849-langId-en,00.html. Accessed August, 2007.
3. Thomas H, Reeves G, Key T. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control 1997;8:922-928.
4. Beatson G. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases. Lancet 1896;2:104-107.
5. Altundag K, Ibrahim NK. Aromatase inhibitors in breast cancer: an overview. Oncologist 2006;11:553-562.
6. Liehr JG. Is estradiol a genotoxic mutagenic carcinogen? Endocr Rev 2000;21:40-54.
7. Jongen VHWM, Sluijmer AV, Heineman MJ. The postmenopausal ovary as an androgen-producing gland; hypothesis on the etiology of endometrial cancer. Maturitas 2002;43:77-85.
8. Castagnetta LA, Granata OM, Traina A, et al. Tissue content of hydroxyestrogens in relation to survival of breast cancer patients. Clin Cancer Res 2002;8:3146-3155.
9. Liehr JG. Dual role of oestrogens as hormones and pro-carcinogens: tumour initiation by metabolic activation of oestrogens. Eur J Cancer Prev 1997;6:3-10.
10. Walker RA, Martin CV. The aged breast. J Pathol 2007;211:232-240.
11. Simpson ER, Misso M, Hewitt KN, et al. Estrogen - the good, the bad, and the unexpected. Endocr Rev 2005;26:322-330.
12. Labrie F. Intracrinology. Mol Cell Endocrinol 1991;78:C113-C118.
13. Simpson ER. Sources of estrogen and their importance. J Steroid Biochem Mol Biol 2003;86:225-230.
14. Wilson JD, Aiman J, MacDonald PC. The pathogenesis of gynecomastia. Adv Intern Med 1980;25:1-32.
15. Velasco I, Rueda J, Acien P. Aromatase expression in endometriotic tissues and cell cultures of patients with endometriosis. Mol Hum Reprod 2006;12:377-381.
16. Tekmal RR, Ramachandra N, Gubba S, et al. Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities. Cancer Res 1996;56:3180-3185.
17. Misso ML JC, Adams JC, Tran J, et al. Adipose aromatase gene expression is greater in older women and is unaffected by postmenopausal estrogen therapy. Menopause 2005;12:210-215.
18. Pasqualini JR, Chetrite G, Blacker C, et al. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J Clin Endocrinol Metab 1996;81:1460-1464.
19. Cleland WH, Mendelson CR, Simpson ER. Effects of aging and obesity on aromatase activity of human adipose cells. J Clin Endocrinol Metab 1985;60:174-177.
20. Honma N, Takubo K, Sawabe M, et al. Estrogen-metabolizing enzymes in breast cancers from women over the age of 80 years. J Clin Endocrinol Metab 2006;91:607-613.
21. Purohit A, Ghilchik MW, Duncan L, et al. Aromatase activity and interleukin-6 production by normal and malignant breast tissues. J Clin Endocrinol Metab 1995;80:3052-3058.
22. Bonneterre J. Aromatase inhibitors as first line treatment: treatment cascade after failure of aromatase inhibitors. Breast Cancer Res Treat 2003;81:57-61.
23. Miller W. Aromatase inhibitors and breast cancer. Minerva Endocrinol 2006;31:27-46.
24. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbB-1- and/or erbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-3816.
25. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 1998;83:1142-1152.
26. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-461.
27. Beslija S, Bonneterre J, Burstein H, et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 2007;18:215-225.
28. Goss PE, Ingle JN, Martino S, et al. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol 2007;25:2006-2011.
29. Lonning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005;23:5126-5137.
30. Harper-Wynne C, Ross G, Sacks N, et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 2002;11:614-621.
31. NCI 2007. Available at: http://www.cancer.gov/bcrisktool/Default.aspx. Accessed January, 2007.
32. Euhus DM, Leitch AM, Huth JF, Peters GN. Limitations of the Gail model in the specialized breast cancer risk assessment clinic. Breast J 2002;8:23-27.
33. Byng JW, Boyd NF, Little L, et al. Symmetry of projection in the quantitative analysis of mammographic images. Eur J Cancer Prev 1996;5:319-327.
34. Raundahl J, Nielsen M, Olsen OF, Bagger YZ. Effect of projective viewpoint in detecting temporal density changes. Proceedings of SPIE - The International Society for Optical Engineering, 2004, pp 85-92.
35. Glide-Hurst CK, Duric N, Littrup P. A new method for quantitative analysis of mammographic density. Med Phys 2007;34:4491-4498.
36. American College of Radiology. Breast Imaging Reporting and Data System (BIRADS), 5th ed. Reston, VA: American College of Radiology, 2003.
37. Harvey J. Quantitative assessment of percent breast density: analog versus digital acquisition. Technol Cancer Res Treat 2004;3:611-616.
38. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006;15:1159-1169.
39. Boyd NF, Rommens JM, Vogt K, et al. Mammographic breast density as an intermediate phenotype for breast cancer. Lancet Oncol 2005;6:798-808.
40. Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007;356:227-236.
41. Mitchell G, Antoniou AC, Warren R, et al. Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Res 2006;66:1866-1872.
42. Boyd NF, Jensen HM, Cooke G, Han HL. Relationship between mammographic and histological risk factors for breast cancer. J Natl Cancer Inst 1992;84:1170-1179.
43. Van Gils CH, Hendriks JHCL, Holland R, et al. Changes in mammographic breast density and concomitant changes in breast cancer risk. Eur J Cancer Prev 1999;8:509-515.
44. Kerlikowske K, Ichikawa L, Miglioretti DL, et al. Longitudinal measurement of clinical mammographic breast density to improve estimation of breast cancer risk. J Natl Cancer Inst 2007;99:386-395.
45. Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 2003;138:168-175.
46. Sala E, Warren R, McCann J, Duffy S, Day N, Luben R. Mammographic parenchymal patterns and mode of detection: implications for the breast screening programme. J Med Screen 1998;5:207-212.
47. Boyd NF, Lockwood GA, Martin LJ, et al. Mammographic densities and breast cancer risk. Breast Dis 1998;10:113-126.
48. Chow CK, Venzon D, Jones EC, Premkumar A, O'Shaughnessy J, Zujewski J. Effect of tamoxifen on mammographic density. Cancer Epidemiol Biomarkers Prev 2000;9:917-921.
49. Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst 2004;96:621-628.
50. Weitzel JN, Buys SS, Sherman WH, et al. Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers. Clin Cancer Res 2007;13:654-658.
51. Kutlu T, Ficicioglu C, Basaran T, Basaran E, Topaloglu T. Mammographic breast density changes after 1 year of tibolone use. Maturitas 2004;48:133-136.
52. Maskarinec G, Williams AE, Carlin L. Mammographic densities in a one-year isoflavone intervention. Eur J Cancer Prev 2003;12:165-169.
53. Boyd NF, Greenberg C, Lockwood G, et al. Effects at two years of a low-fat, high-carbohydrate diet on radiologic features of the breast: results from a randomized trial. Canadian Diet and Breast Cancer Prevention Study Group. J Natl Cancer Inst 1997;89:488-496.
54. Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst 2003;95:30-37.
55. McTiernan A, Martin CF, Peck JD, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative Randomized Trial. J Natl Cancer Inst 2005;97:1366-1376.
56. Persson I, Thurfjell E, Holmberg L. Effect of estrogen and estrogenprogestin replacement regimens on mammographic breast parenchymal density. J Clin Oncol 1997;15:3201-3207.
57. Topal NB, Ayhan S, Topal U, Bilgin T. Effects of hormone replacement therapy regimens on mammographic breast density: the role of progestins. J Obstet Gynaecol Res 2006;32:305-308.
58. Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S. Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy. JAMA 2001;285:171-176.
59. Leung W, Goldberg F, Zee B, Sterns E. Mammographic density in women on postmenopausal hormone replacement therapy. Surgery 1997;122:669-674.
60. Palomares MR, Machia JRB, Lehman CD, Daling JR, McTiernan A. Mammographic density correlation with Gail model breast cancer risk estimates and component risk factors. Cancer Epidemiol Biomarkers Prev 2006;15:1324-1330.
61. Harvey JA, Bovbjerg VE. Quantitative assessment of mammographic breast density: relationship with breast cancer risk. Radiology 2004;230:29-41.
62. Gasco M, Argusti A, Bonanni B, Decensi A. SERMs in chemoprevention of breast cancer. Eur J Cancer 2005;41:1980-1989.
63. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296-300.
64. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431-2442.
65. Lonning PE. Exemestane for breast cancer prevention: a feasible strategy? Clin Cancer Res 2005;11:918s-924s.
66. Wickerham DL, Fourchotte V. An update on breast cancer prevention trials. Int J Gynecol Cancer 2006;16(Suppl 2):498-501.
67. Richardson H, Johnston D, Pater J, Goss P. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr Oncol 2007;14:89-96.
68. Jackson RD, Wactawski-Wende J, LaCroix AZ, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Trial. J Bone Miner Res 2006;21:817-828.
69. Lindsay R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 1990;76:290-295.
70. Khastgir G, Studd J, Holland N, Alaghband-Zadeh J, Sims TJ, Bailey AJ. Anabolic effect of long-term estrogen replacement on bone collagen in elderly postmenopausal women with osteoporosis. Osteoporos Int 2001;12:465-470.
71. Hurd WW, Amesse LS, Randolph JF Jr. Menopause. In: Berek JS, ed. Novak's Gynecology, 13th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:1109-1139.
72. Grady D. A 60-year-old woman trying to discontinue hormone replacement therapy. JAMA 2002;287:2130-2137.
73. Manson JE, Allison MA, Rossouw JE, et al. Estrogen therapy and coronary-artery calcification. N Engl J Med 2007;356:2591-2602.
74. Goss PE, Strasser-Weippl K. Prevention strategies with aromatase inhibitors. Clin Cancer Res 2004;10:372S-379S.
75. Kendall A, Dowsett M. Novel concepts for the chemoprevention of breast cancer through aromatase inhibition. Endocr Relat Cancer 2006;13:827-837.
76. Writing Group for the Women's Health Initiative I. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
77. Anderson GL, Limacher M. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
78. Fabian C, Kimler B, Zalles C, et al. Reduction in proliferation with six months of letrozole in women on hormone replacement therapy. Breast Cancer Res Treat 2007;106:75-84.